{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:43:00Z","timestamp":1790764980076,"version":"4.1.0"},"reference-count":183,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008258","name":"Hyundai Hope On Wheels","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008258","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00121","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:49:06Z","timestamp":1581641346000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["Neoantigens in Hematologic Malignancies"],"prefix":"10.3389","volume":"11","author":[{"given":"Melinda A.","family":"Biernacki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Bleakley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.0105-2896.2005.00320.x","article-title":"Antigen processing and presentation","volume":"207","author":"Cresswell","year":"2005","journal-title":"Immunol Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nri2368","article-title":"The known unknowns of antigen processing and presentation","volume":"8","author":"Vyas","year":"2008","journal-title":"Nat Rev Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1146\/annurev-immunol-032712-095910","article-title":"Pathways of antigen processing","volume":"31","author":"Blum","year":"2013","journal-title":"Annu Rev Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science."},{"key":"B5","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nm.3161","article-title":"Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells","volume":"19","author":"Robbins","year":"2013","journal-title":"Nat Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","article-title":"Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer","volume":"24","author":"Zacharakis","year":"2018","journal-title":"Nat Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature."},{"key":"B9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature."},{"key":"B10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature."},{"key":"B11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat Rev Cancer."},{"key":"B12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41591-019-0434-2","article-title":"Immunogenic neoantigens derived from gene fusions stimulate T cell responses","volume":"25","author":"Yang","year":"2019","journal-title":"Nat Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2014-04-567933","article-title":"Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia","volume":"124","author":"Rajasagi","year":"2014","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature."},{"key":"B15","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1084\/jem.191.6.961","article-title":"Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer","volume":"191","author":"Koopman","year":"2000","journal-title":"J Exp Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"A40","DOI":"10.1016\/S0264-410X(02)00386-9","article-title":"HLA class I antigen loss, tumor immune escape and immune selection","volume":"20","author":"Campoli","year":"2002","journal-title":"Vaccine."},{"key":"B17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00262-016-1947-x","article-title":"Rejection versus escape: the tumor MHC dilemma","volume":"66","author":"Garrido","year":"2017","journal-title":"Cancer Immunol Immunother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/nbt.3344","article-title":"Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes","volume":"33","author":"Shukla","year":"2015","journal-title":"Nat Biotechnol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/j.1399-0039.1998.tb03082.x","article-title":"Mutations of the \u03b22-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides","volume":"52","author":"Benitez","year":"1998","journal-title":"Tissue Antigens."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1038\/s41467-018-06300-3","article-title":"Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA","volume":"9","author":"Paulson","year":"2018","journal-title":"Nat Commun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"25208","DOI":"10.1038\/srep25208","article-title":"Exposure to Melan-A\/MART-126\u201335 tumor epitope specific CD8(+)T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS)","volume":"6","author":"Ebstein","year":"2016","journal-title":"Sci Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/s41591-019-0596-y","article-title":"Developing neoantigen-targeted T cell-based treatments for solid tumors","volume":"25","author":"Yamamoto","year":"2019","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nbt.3800","volume":"35","year":"2017","journal-title":"Nat Biotechnol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1182\/blood.V85.10.2680.bloodjournal85102680","article-title":"Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules","volume":"85","author":"Bocchia","year":"1995","journal-title":"Blood."},{"key":"B29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/9858","article-title":"Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices","volume":"17","author":"Sturniolo","year":"1999","journal-title":"Nat Biotechnol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/bioinformatics\/17.12.1236","article-title":"ProPred: prediction of HLA-DR binding sites","volume":"17","author":"Singh","year":"2001","journal-title":"Bioinformatics."},{"key":"B31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1471-2105-6-132","article-title":"Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method","volume":"6","author":"Peters","year":"2005","journal-title":"BMC Bioinformatics."},{"key":"B32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/00822942-200605010-00008","article-title":"MHCPred 2.0: an updated quantitative T-cell epitope prediction server","volume":"5","author":"Guan","year":"2006","journal-title":"Appl Bioinformatics."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1745-7580-4-2","article-title":"Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries","volume":"4","author":"Sidney","year":"2008","journal-title":"Immunome Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e1000048","DOI":"10.1371\/journal.pcbi.1000048","article-title":"A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach","volume":"4","author":"Wang","year":"2008","journal-title":"PLoS Comput Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00251-008-0341-z","article-title":"NetMHCpan, a method for MHC class I binding prediction beyond humans","volume":"61","author":"Hoof","year":"2009","journal-title":"Immunogenetics."},{"key":"B36","doi-asserted-by":"publisher","first-page":"W525","DOI":"10.1093\/nar\/gks438","article-title":"Immune epitope database analysis resource","volume":"40","author":"Kim","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: Improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data","volume":"199","author":"Jurtz","year":"2017","journal-title":"J Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/imm.12889","article-title":"Improved methods for predicting peptide binding affinity to MHC class II molecules","volume":"154","author":"Jensen","year":"2018","journal-title":"Immunology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13073-018-0594-6","article-title":"Footprints of antigen processing boost MHC class II natural ligand predictions","volume":"10","author":"Barra","year":"2018","journal-title":"Genome Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nbt.4313","article-title":"Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification","volume":"37","author":"Bulik-Sullivan","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41587-019-0280-2","article-title":"Predicting HLA class II antigen presentation through integrated deep learning","volume":"37","author":"Chen","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s41587-019-0289-6","article-title":"Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes","volume":"37","author":"Racle","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.immuni.2019.08.012","article-title":"Defining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction","volume":"51","author":"Abelin","year":"2019","journal-title":"Immunity"},{"key":"B44","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00251-019-01122-z","article-title":"Improved peptide-MHC class II interaction prediction through integration of eluted ligand and peptide affinity data","volume":"71","author":"Garde","year":"2019","journal-title":"Immunogenetics."},{"key":"B45","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00251-018-1054-6","article-title":"Cross-modality deep learning-based prediction of TAP binding and naturally processed peptide","volume":"70","author":"Besser","year":"2018","journal-title":"Immunogenetics."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00018-005-4528-2","article-title":"Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding","volume":"62","author":"Tenzer","year":"2005","journal-title":"Cell Mol Life Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00251-014-0815-0","article-title":"Role of peptide processing predictions in T cell epitope identification: contribution of different prediction programs","volume":"67","author":"Calis","year":"2015","journal-title":"Immunogenetics."},{"key":"B48","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1186\/1471-2105-11-479","article-title":"Computational analysis and modeling of cleavage by the immunoproteasome and the constitutive proteasome","volume":"11","author":"Diez-Rivero","year":"2010","journal-title":"BMC Bioinformatics."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.3389\/fimmu.2018.01795","article-title":"Determination of a predictive cleavage motif for eluted major histocompatibility complex class II ligands","volume":"9","author":"Paul","year":"2018","journal-title":"Front Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1745-7580-2-3","article-title":"PRED(TAP): a system for prediction of peptide binding to the human transporter associated with antigen processing","volume":"2","author":"Zhang","year":"2006","journal-title":"Immunome Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12859-018-2561-z","article-title":"Predicting peptide presentation by major histocompatibility complex class I: an improved machine learning approach to the immunopeptidome","volume":"20","author":"Boehm","year":"2019","journal-title":"BMC Bioinformatics."},{"key":"B52","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/1471-2105-8-424","article-title":"Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction","volume":"8","author":"Larsen","year":"2007","journal-title":"BMC Bioinformatics."},{"key":"B53","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00251-005-0781-7","article-title":"The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage","volume":"57","author":"Nielsen","year":"2005","journal-title":"Immunogenetics."},{"key":"B54","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.coi.2018.04.016","article-title":"Why do proteases mess up with antigen presentation by re-shuffling antigen sequences?","volume":"52","author":"Liepe","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1126\/science.aaf4384","article-title":"A large fraction of HLA class I ligands are proteasome-generated spliced peptides","volume":"354","author":"Liepe","year":"2016","journal-title":"Science."},{"key":"B56","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2326-6066.CIR-13-0227","article-title":"HLA-binding properties of tumor neoepitopes in humans","volume":"2","author":"Fritsch","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/leu.2014.233","article-title":"Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy","volume":"29","author":"Berlin","year":"2015","journal-title":"Leukemia."},{"key":"B58","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1182\/blood-2018-07-866830","article-title":"The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy","volume":"133","author":"Bilich","year":"2019","journal-title":"Blood."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e1316438","DOI":"10.1080\/2162402X.2017.1316438","article-title":"HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy","volume":"7","author":"Nelde","year":"2018","journal-title":"Oncoimmunology."},{"key":"B60","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.immuni.2017.02.007","article-title":"Mass Spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction","volume":"46","author":"Abelin","year":"2017","journal-title":"Immunity."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1021\/pr700761w","article-title":"Identification of breast cancer peptide epitopes presented by HLA-A*0201","volume":"7","author":"Hawkins","year":"2008","journal-title":"J Proteome Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.4049\/jimmunol.1501721","article-title":"The length distribution of class I-restricted T cell epitopes is determined by both peptide supply and MHC allele-specific binding preference","volume":"196","author":"Trolle","year":"2016","journal-title":"J Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1074\/mcp.M114.042812","article-title":"Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation","volume":"14","author":"Bassani-Sternberg","year":"2015","journal-title":"Mol Cell Proteomics."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.3389\/fimmu.2018.01716","article-title":"Predicting antigen presentation-what could we learn from a million peptides?","volume":"9","author":"Gfeller","year":"2018","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nature24473","article-title":"A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy","volume":"551","author":"Luksza","year":"2017","journal-title":"Nature."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1158\/2326-6066.CIR-19-0155","article-title":"Machine-learning prediction of tumor antigen immunogenicity in the selection of therapeutic epitopes","volume":"7","author":"Smith","year":"2019","journal-title":"Cancer Immunol Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3389\/fimmu.2019.02047","article-title":"Structure based prediction of neoantigen immunogenicity","volume":"10","author":"Riley","year":"2019","journal-title":"Front Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cels.2019.08.009","article-title":"Neoantigen dissimilarity to the self-proteome predicts immunogenicity and response to immune checkpoint blockade","volume":"9","author":"Richman","year":"2019","journal-title":"Cell Syst"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e1492508","DOI":"10.1080\/2162402X.2018.1492508","article-title":"Predicting T cell recognition of MHC class I restricted neoepitopes","volume":"7","author":"Kosaloglu-Yalcin","year":"2018","journal-title":"Oncoimmunology."},{"key":"B70","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1172\/JCI98689","article-title":"Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma","volume":"128","author":"Veatch","year":"2018","journal-title":"J Clin Invest."},{"key":"B72","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nm.4051","article-title":"Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients","volume":"22","author":"Gros","year":"2016","journal-title":"Nat Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1172\/JCI97482","article-title":"Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia","volume":"129","author":"van der Lee","year":"2019","journal-title":"J Clin Invest."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cell.2019.07.009","article-title":"T-Scan: a genome-wide method for the systematic discovery of T cell epitopes","volume":"178","author":"Kula","year":"2019","journal-title":"Cell."},{"key":"B76","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1182\/blood-2009-12-260539","article-title":"Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells","volume":"115","author":"Bleakley","year":"2010","journal-title":"Blood."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1126\/science.aaf2288","article-title":"Targeting of cancer neoantigens with donor-derived T cell receptor repertoires","volume":"352","author":"Stronen","year":"2016","journal-title":"Science."},{"key":"B78","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1158\/0008-5472.CAN-16-1303","article-title":"Mutational landscape of pediatric acute lymphoblastic leukemia","volume":"77","author":"Ding","year":"2017","journal-title":"Cancer Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1200\/JCO.2016.70.7836","article-title":"Genetic basis of acute lymphoblastic leukemia","volume":"35","author":"Iacobucci","year":"2017","journal-title":"J Clin Oncol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","year":"2013","journal-title":"N Engl J Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature."},{"key":"B83","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature14666","article-title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia","volume":"526","author":"Puente","year":"2015","journal-title":"Nature."},{"key":"B84","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1182\/blood-2018-05-848473","article-title":"Mutational landscape of myelodysplastic\/myeloproliferative neoplasm-unclassifiable","volume":"132","author":"Bose","year":"2018","journal-title":"Blood."},{"key":"B85","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood.2019000519","article-title":"Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms","volume":"134","author":"Schischlik","year":"2019","journal-title":"Blood."},{"key":"B86","doi-asserted-by":"publisher","first-page":"E166","DOI":"10.1073\/pnas.1416389112","article-title":"HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)","volume":"112","author":"Kowalewski","year":"2015","journal-title":"Proc Natl Acad Sci USA."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1182\/blood-2015-04-640532","article-title":"The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy","volume":"126","author":"Walz","year":"2015","journal-title":"Blood."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e0219547","DOI":"10.1371\/journal.pone.0219547","article-title":"Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin","volume":"14","author":"Narayan","year":"2019","journal-title":"PLoS ONE."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia","volume":"13","author":"van Dongen","year":"1999","journal-title":"Leukemia"},{"key":"B90","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL recombinome of acute leukemias in 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1182\/blood.V87.6.2171.bloodjournal8762171","article-title":"Mutations in the Wilms' tumor gene WT1 in leukemias","volume":"87","author":"King-Underwood","year":"1996","journal-title":"Blood."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1182\/blood-2018-03-837468","article-title":"Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis","volume":"132","author":"Pronier","year":"2018","journal-title":"Blood."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1609128","DOI":"10.1155\/2019\/1609128","article-title":"Mutated WT1, FLT3-ITD, and NUP98-NSD1 fusion in various combinations define a poor prognostic group in pediatric acute myeloid leukemia","volume":"2019","author":"Niktoreh","year":"2019","journal-title":"J Oncol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41375-018-0319-2","article-title":"Single cell analysis of clonal architecture in acute myeloid leukaemia","volume":"33","author":"Potter","year":"2019","journal-title":"Leukemia."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1182\/blood-2008-12-192039","article-title":"WT1 mutations in T-ALL","volume":"114","author":"Tosello","year":"2009","journal-title":"Blood."},{"key":"B96","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Weng","year":"2004","journal-title":"Science."},{"key":"B97","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrc1880","article-title":"Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia","volume":"6","author":"Grabher","year":"2006","journal-title":"Nat Rev Cancer."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood-2016-10-706465","article-title":"The genetics and molecular biology of T-ALL","volume":"129","author":"Girardi","year":"2017","journal-title":"Blood."},{"key":"B99","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc.2017.109","article-title":"Targeting mutant p53 for efficient cancer therapy","volume":"18","author":"Bykov","year":"2018","journal-title":"Nat Rev Cancer."},{"key":"B100","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/leu.2016.263","article-title":"The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases","volume":"31","author":"Stengel","year":"2017","journal-title":"Leukemia."},{"key":"B101","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1182\/blood-2011-11-366062","article-title":"Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies","volume":"119","author":"Xu-Monette","year":"2012","journal-title":"Blood."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1182\/blood-2010-08-299990","article-title":"Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?","volume":"117","author":"Falini","year":"2011","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"eaax7918","DOI":"10.1126\/scitranslmed.aax7918","article-title":"Neoantigen quality, not quantity","volume":"11","author":"McGranahan","year":"2019","journal-title":"Sci Transl Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1182\/blood-2013-04-496844","article-title":"Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)","volume":"122","author":"Greiner","year":"2013","journal-title":"Blood."},{"key":"B107","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1200\/JCO.2011.41.1116","article-title":"Donor lymphocyte infusion induces polyspecific CD8+ T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation","volume":"31","author":"Hofmann","year":"2013","journal-title":"J Clin Oncol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/leu.2014.116","article-title":"Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy","volume":"28","author":"Schneider","year":"2014","journal-title":"Leukemia."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1158\/2159-8290.CD-18-1356","article-title":"Immune checkpoint blockade enhances shared neoantigen-induced T-cell immunity directed against mutated calreticulin in myeloproliferative neoplasms","volume":"9","author":"Cimen Bozkus","year":"2019","journal-title":"Cancer Discov."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1182\/blood.V81.5.1369.1369","article-title":"Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml\/RAR alpha present in acute promyelocytic leukemia cells","volume":"81","author":"Gambacorti-Passerini","year":"1993","journal-title":"Blood."},{"key":"B111","first-page":"593","article-title":"Lack of T-cell-mediated recognition of the fusion region of the pml\/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients","volume":"2","author":"Dermime","year":"1996","journal-title":"Clin Cancer Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"eaat8549","DOI":"10.1126\/scitranslmed.aat8549","article-title":"Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8+ T cell responses","volume":"11","author":"Zamora","year":"2019","journal-title":"Sci Transl Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1172\/JCI3126","article-title":"Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia","volume":"102","author":"Yotnda","year":"1998","journal-title":"J Clin Invest."},{"key":"B114","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1182\/blood-2010-12-325035","article-title":"The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed","volume":"118","author":"Popovic","year":"2011","journal-title":"Blood."},{"key":"B115","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40425-018-0386-y","article-title":"Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies","volume":"6","author":"Tubb","year":"2018","journal-title":"J Immunother Cancer."},{"key":"B116","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/leu.2016.290","article-title":"The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms","volume":"31","author":"Holmstrom","year":"2017","journal-title":"Leukemia."},{"key":"B117","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1182\/blood.V98.10.2887","article-title":"Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein","volume":"98","author":"Clark","year":"2001","journal-title":"Blood."},{"key":"B118","doi-asserted-by":"publisher","first-page":"5761","DOI":"10.1158\/1078-0432.CCR-12-1182","article-title":"Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients","volume":"18","author":"Cai","year":"2012","journal-title":"Clin Cancer Res."},{"key":"B119","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ijc.29366","article-title":"CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes","volume":"137","author":"Vauchy","year":"2015","journal-title":"Int J Cancer."},{"key":"B120","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1158\/2326-6066.CIR-15-0188","article-title":"Identification of T-cell receptors targeting KRAS-mutated human tumors","volume":"4","author":"Wang","year":"2016","journal-title":"Cancer Immunol Res."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI123791","article-title":"Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers","volume":"129","author":"Malekzadeh","year":"2019","journal-title":"J Clin Invest."},{"key":"B122","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1158\/2326-6066.CIR-18-0686","article-title":"Immunologic recognition of a shared p53 mutated neoantigen in a patient with metastatic colorectal cancer","volume":"7","author":"Lo","year":"2019","journal-title":"Cancer Immunol Res."},{"key":"B123","doi-asserted-by":"publisher","first-page":"869","DOI":"10.18632\/oncotarget.26617","article-title":"Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia","volume":"10","author":"Forghieri","year":"2019","journal-title":"Oncotarget."},{"key":"B124","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood."},{"key":"B125","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","article-title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","volume":"127","author":"Grimwade","year":"2016","journal-title":"Blood."},{"key":"B126","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood."},{"key":"B127","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"B128","first-page":"1985","article-title":"TEL\/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis","volume":"9","author":"Shurtleff","year":"1995","journal-title":"Leukemia."},{"key":"B129","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1182\/blood.V85.12.3662.bloodjournal85123662","article-title":"The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion","volume":"85","author":"Romana","year":"1995","journal-title":"Blood."},{"key":"B130","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1182\/blood.V86.11.4263.bloodjournal86114263","article-title":"High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia","volume":"86","author":"Romana","year":"1995","journal-title":"Blood."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1200\/JCO.1997.15.3.1150","article-title":"TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance","volume":"15","author":"Rubnitz","year":"1997","journal-title":"J Clin Oncol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1038\/leu.2016.233","article-title":"The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms","volume":"30","author":"Holmstrom","year":"2016","journal-title":"Leukemia."},{"key":"B134","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1182\/blood.V86.12.4603.bloodjournal86124603","article-title":"BCR\/ABL P210 and P190 cause distinct leukemia in transgenic mice","volume":"86","author":"Voncken","year":"1995","journal-title":"Blood."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1073\/pnas.89.4.1468","article-title":"T-cell immunity to the joining region of p210BCR-ABL protein","volume":"89","author":"Chen","year":"1992","journal-title":"Proc Natl Acad Sci USA."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00262-009-0675-x","article-title":"Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?","volume":"58","author":"Riley","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"B137","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1182\/blood-2016-07-731091","article-title":"BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors","volume":"129","author":"Comoli","year":"2017","journal-title":"Blood."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1073\/pnas.69.6.1540","article-title":"Myeloma proteins as tumor-specific transplantation antigens","volume":"69","author":"Lynch","year":"1972","journal-title":"Proc Natl Acad Sci USA."},{"key":"B139","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nrc2717","article-title":"Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures","volume":"9","author":"Bendandi","year":"2009","journal-title":"Nat Rev Cancer."},{"key":"B140","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nature21433","article-title":"Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens","volume":"543","author":"Khodadoust","year":"2017","journal-title":"Nature."},{"key":"B141","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1182\/blood-2018-06-845156","article-title":"B-cell lymphomas present immunoglobulin neoantigens","volume":"133","author":"Khodadoust","year":"2019","journal-title":"Blood."},{"key":"B142","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1182\/blood-2009-06-229112","article-title":"Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance","volume":"115","author":"Henry","year":"2010","journal-title":"Blood."},{"key":"B143","doi-asserted-by":"publisher","first-page":"e1219825","DOI":"10.1080\/2162402X.2016.1219825","article-title":"HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy","volume":"6","author":"Nelde","year":"2017","journal-title":"Oncoimmunology."},{"key":"B144","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrc1097","article-title":"RAS oncogenes: the first 30 years","volume":"3","author":"Malumbres","year":"2003","journal-title":"Nat Rev Cancer."},{"key":"B145","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrc2109","article-title":"Hyperactive Ras in developmental disorders and cancer","volume":"7","author":"Schubbert","year":"2007","journal-title":"Nat Rev Cancer."},{"key":"B146","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/blood-2012-05-378596","article-title":"Targeting oncogenic Ras signaling in hematologic malignancies","volume":"120","author":"Ward","year":"2012","journal-title":"Blood."},{"key":"B147","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of Ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res."},{"key":"B148","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1038\/s41375-019-0444-6","article-title":"KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival","volume":"33","author":"Vendramini","year":"2019","journal-title":"Leukemia."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1242\/jcs.182873","article-title":"RAS isoforms and mutations in cancer at a glance","volume":"129","author":"Hobbs","year":"2016","journal-title":"J Cell Sci."},{"key":"B150","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrc3760","article-title":"Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond","volume":"14","author":"Holderfield","year":"2014","journal-title":"Nat Rev Cancer."},{"key":"B151","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med."},{"key":"B152","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2011-08-368209","article-title":"The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms","volume":"119","author":"Arcaini","year":"2012","journal-title":"Blood."},{"key":"B153","doi-asserted-by":"publisher","first-page":"238ra71","DOI":"10.1126\/scitranslmed.3008004","article-title":"Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia","volume":"6","author":"Chung","year":"2014","journal-title":"Sci Transl Med."},{"key":"B154","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1084\/jem.20130977","article-title":"BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups","volume":"211","author":"Berres","year":"2014","journal-title":"J Exp Med."},{"key":"B155","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/humu.23035","article-title":"TP53 Variations in human cancers: new lessons from the IARC TP53 database and genomics data","volume":"37","author":"Bouaoun","year":"2016","journal-title":"Hum Mutat."},{"key":"B156","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41467-019-08304-z","article-title":"Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients","volume":"10","author":"Cafri","year":"2019","journal-title":"Nat Commun."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1158\/0008-5472.CAN-03-3231","article-title":"CD4+ T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation","volume":"64","author":"Sharkey","year":"2004","journal-title":"Cancer Res."},{"key":"B158","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/mt.2016.51","article-title":"Stable, nonviral expression of mutated tumor neoantigen-specific t-cell receptors using the sleeping beauty transposon\/transposase system","volume":"24","author":"Deniger","year":"2016","journal-title":"Mol Ther."},{"key":"B160","doi-asserted-by":"publisher","first-page":"e122467","DOI":"10.1172\/jci.insight.122467","article-title":"Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy","volume":"3","author":"Yossef","year":"2018","journal-title":"JCI Insight."},{"key":"B161","doi-asserted-by":"publisher","first-page":"288ra78","DOI":"10.1126\/scitranslmed.aaa7014","article-title":"Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma","volume":"7","author":"Noonan","year":"2015","journal-title":"Sci Transl Med."},{"key":"B162","doi-asserted-by":"publisher","first-page":"174ra27","DOI":"10.1126\/scitranslmed.3004916","article-title":"Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients","volume":"5","author":"Chapuis","year":"2013","journal-title":"Sci Transl Med."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2011-02-337089","article-title":"Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety","volume":"118","author":"Ochi","year":"2011","journal-title":"Blood."},{"key":"B164","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1182\/blood.V95.1.286","article-title":"HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide","volume":"95","author":"Ohminami","year":"2000","journal-title":"Blood."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat Med."},{"key":"B166","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1084\/jem.188.12.2357","article-title":"The central role of CD4+ T cells in the antitumor immune response","volume":"188","author":"Hung","year":"1998","journal-title":"J Exp Med."},{"key":"B167","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1182\/blood-2017-07-791608","article-title":"Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse","volume":"131","author":"Dossa","year":"2018","journal-title":"Blood."},{"key":"B168","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia."},{"key":"B169","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med."},{"key":"B170","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/PPO.0000000000000378","article-title":"T-cell receptor-based immunotherapy for hematologic malignancies","volume":"25","author":"Biernacki","year":"2019","journal-title":"Cancer J."},{"key":"B171","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Invest."},{"key":"B172","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.ymthe.2018.05.007","article-title":"PiggyBac-engineered T cells expressing CD19-specific CARs that Lack IgG1 Fc spacers have potent activity against B-ALL xenografts","volume":"26","author":"Bishop","year":"2018","journal-title":"Mol Ther."},{"key":"B173","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1074\/mcp.M116.060301","article-title":"Proteome profiling outperforms transcriptome profiling for coexpression based gene function prediction","volume":"16","author":"Wang","year":"2017","journal-title":"Mol Cell Proteomics"},{"key":"B174","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.3389\/fimmu.2018.02503","article-title":"Efficient and non-genotoxic RNA-based engineering of human T cells using tumor-specific T cell receptors with minimal TCR mispairing","volume":"9","author":"Campillo-Davo","year":"2018","journal-title":"Front Immunol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","article-title":"Toward eliminating HLA class I expression to generate universal cells from allogeneic donors","volume":"122","author":"Torikai","year":"2013","journal-title":"Blood."},{"key":"B176","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41568-019-0106-z","article-title":"Immune control by amino acid catabolism during tumorigenesis and therapy","volume":"19","author":"Lemos","year":"2019","journal-title":"Nat Rev Cancer."},{"key":"B177","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrc.2016.16","article-title":"Vaccines for established cancer: overcoming the challenges posed by immune evasion","volume":"16","author":"van der Burg","year":"2016","journal-title":"Nat Rev Cancer."},{"key":"B178","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3109\/10428194.2014.953150","article-title":"Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics","volume":"56","author":"Fukuno","year":"2015","journal-title":"Leuk Lymphoma."},{"key":"B179","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","article-title":"Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment","volume":"122","author":"Mussai","year":"2013","journal-title":"Blood."},{"key":"B180","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","article-title":"PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model","volume":"114","author":"Zhang","year":"2009","journal-title":"Blood."},{"key":"B181","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.4049\/jimmunol.167.10.6021","article-title":"Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways","volume":"167","author":"Buggins","year":"2001","journal-title":"J Immunol."},{"key":"B182","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41375-018-0175-0","article-title":"Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML","volume":"32","author":"Bruck","year":"2018","journal-title":"Leukemia."},{"key":"B183","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semcancer.2013.08.011","article-title":"The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies","volume":"24","author":"Burger","year":"2014","journal-title":"Semin Cancer Biol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00121\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:49:09Z","timestamp":1581641349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00121\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":183,"alternative-id":["10.3389\/fimmu.2020.00121"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00121","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]},"article-number":"121"}}